Open AccessBortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Author(s) -
Laura Rosiñol,
Albert Oriol,
Rafael Ríos,
Anna Sureda,
María Jesús Blanchard,
MiguelTeodoro Hernández,
R. MartínezMartínez,
José M. Moraleda,
Isidro Jarque,
Juan Bargay,
Mercedes Gironella,
Felipe de Arriba,
Luis Palomera,
Yolanda GonzálezMontes,
Josep Martí,
Isabel Krsnik,
José-María Arguiñano,
María E. González,
Ana Pilar González,
Luis Felipe Casado,
Lucía LópezAnglada,
Bruno Paiva,
MaríaVictoria Mateos,
Jesús F. San Miguel,
Juan José Lahuerta,
Joan Bladé
Publication year - 2019
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2019000241
Subject(s) - lenalidomide , induction therapy , dexamethasone , multiple myeloma , bortezomib , medicine , minimal residual disease , oncology , maintenance therapy , toxicity , autologous stem cell transplantation , thalidomide , bone marrow , chemotherapy
Key Points VRD was effective and well tolerated before ASCT; 33.4% complete response/28.8% minimal residual disease–negative after 6 induction cycles. Responses deepened with VRD throughout induction and over the course of treatment with few discontinuations due to toxicity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom